You are here

Primer Hipertansiyonu Olan Normotansif Bireylerin Birinci Derece Yakınlarında Uyarılmış Endotel ve Renin-Anjiyotensin Sistem Fonksiyonu

The Function of Stimulated Endothelium and Renin-Angiotensin System in Normotensive Subjects With a Family History of Hypertension

Journal Name:

Publication Year:

Abstract (2. Language): 
In this study, the aim is to observe the renin-angiotensin sys¬ tem (RAS) and endothelium after phlebotomy in healthy blood donors. Healthy blood donors were divided into two subgroups according to the presence of hypertensive relatives (Group 1) or not (Group 2). Plasma levels of renin, nitric oxide (NO) and plasminogen activator inhibitor 1 (PAI-1) were studied before and after phlebotomy in each group. 400-500 mL of blood was taken in phlebotomies as usual. NO levels were studied by chemoluminescence method, PAI-1 activity were studied bye chromogenic assay method and plasma renin activity were studied by enzymatic kinetic met¬ hods. No statistically significant difference was observed between the mean baseline plasma renin, NO and PAI-1 level of the two gro¬ ups. Evident increase was observed in the (stimulated) mean plas¬ ma levels of PRA, PAI-1 activity and NO levels after phlebotomy (p<0,001). The increase in mean plasma levels of PRA and PAI-1 activity is more evident in group 1 than group 2 after phlebotomy. Alt¬ hough mean plasma NO levels increased in both groups after phle¬ botomy, increase in group 1 was less than that in group 2. As a conclusion, increased renin, NO and PAI-1 response after phlebotomy in normotensive subjects with or without a family history of hypertension suggests the presence of abnormal RAS and endothelial function in the early stages of hypertension.
Abstract (Original Language): 
Bu çalışmada sağlıklı kan vericilerinde flebotomi sonrası uyarılmış renin-anjiyotensin sistemi (RAS) ve endotel aktivasyonunun tespit edilmesi amaçlandı. Çalışmaya sağlıklı kan vericileri, ailesinde hipertansiyon olmasına göre iki gruba ayrıldı; grup 1, ailede hipertansiyon öyküsü olan ve bu sebeple ileride hipertansiyon gelişimi açısından risk altında olan sağlıklı kan vericileri (Grup 1, n=75, 68E, 7K, 21-52) ve grup 2, ailede hipertansiyon öyküsü olmayan sağlıklı kan vericileri (Grup 2, n=75, 69E, 6K, 21-48). Her iki grupta flebotomi öncesi ve sonrası plazma renin, nitrik oksit (NO) ve plazminojen aktivatör inhibitör tip-1 (PAI-1) düzeyleri ölçüldü. Flebotomide standart olarak 400-500 mL kan alındı. NO dü¬ zeyleri kemolüminesans yöntemi ile, PAI-1 aktivite düzeyi kromojenik esey metodu ile ve plazma renin aktivitesi (PRA) düzeyi ise enzimatik ki¬ netik yöntemler kullanılarak ölçüldü. Ortalama bazal plazma renin, NO, ve PAI-1 aktivite düzeyleri açısından her iki grupta anlamlı bir fark sap¬ tanmadı. Flebotomi sonrası (uyarılmış) ortalama PRA, plazma PAI-1 aktivite ve NO düzeylerinde her iki grupta da belirgin artış saptandı (p<0.001). Flebotomi sonrası ortalama PRA (p<0.05, Şekil 4) ve plazma PAI-1 aktivite (p<0.005, düzey artışı grup 1'de grup 2'ye göre daha belir¬ gindi. Flebotomi sonrası ortalama plazma NO düzeyi her iki grupta da artmasına rağmen grup 1'deki artış grup 2'ye göre daha azdı. Sonuç olarak, ailesinde hipertansiyon öyküsü olan ve olmayan normotansif bireylerde, flebotomi sonrası artmış renin, NO ve PAI- 1 cevabı, hipertansiyonun erken evresinde RAS ve endotel fonksiyon anormalliğinin olduğunu düşündürmektedir.
FULL TEXT (PDF): 
43-49

REFERENCES

References: 

1. An epidemiological approach to describing risk associated with blood pressure level. Final report of the Wor¬king Group on Risk and High Blood Pressure. Hyperten¬sion 1985; 7:641-651.
2. Stamler J, Cirillo M. Dietary salt and renal stone disease. Lancet 1997;349:506-507.
3. Miller JZ, Weinberg MH, Christian JC, et al. Familial re¬semblance in the blood pressure response to sodium rest¬riction. Am J Epidemiol 1987;126:822-830.
4. Catecholamines in essential hypertension. Lancet 1977;1:
1088-1099.
5. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecu¬lar basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-180.
6. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the prometer of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99:1786-1797.
7. O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995;26:2-9.
8. Yarnel WG, Baker IA, Sweeman PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk fac¬tors for ischemic heart disease. The Caerphilly and Spe¬edwell Collaborative Heart Disease Studies. Circulation
1991;83:836-844.
9. Schiffrin EL, Deng LY, Sventek P, et al. Enhanced expres¬sion of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997;15:57-
63.
10. Meade TW, Imeson JD, Gordon D, et al. The epidemi¬ology of plasma renin. Clin Sci 1983;64:273-280.
11. Fisher NDL, Ferri C, Bellini C, et al. Age, gender, and non-modulation. Hypertension 1997;29:980-985.
12. Hunt SC, Cook NR, Oberman A, et al. Angiotensinogen genotype, sodium reduction, weight loss and prevention of hypertension: trials of hypertension prevention, phase II. Hypertension 1998;32:393-401.
13. Vanhoutte PM. Endothelium and control of vascular func¬tion. State of the Art Lecture. Hypertension 1989;13:658-
667.
14. Giner W, Poch E, Bragulat E, et al. Renin-angiotensin sys¬tem genetic polymorphism and salt-sensitivity in essenti¬al hypertension. Hypertension 2000;35:512-517.
15. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
47
£ The Function of Stimulated Endothelium and Renin-Angiotensin System in Normotensive Subjects With a Family History of Hypertension
1995;95: 995-1001.
16. Usalan C, Erdem Y, Çaglar M, et al. Effect of enalapril on exaggerated erythropoeetin response to phlebotomy in erythrocytosic renal transplant patients. Nephrol Dial Transplant 1998;13(11):2884-9.
17. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma; risk factor for recurrent
myocardial infarction. Lancet 1987;2:3-9.
18. Oikiwa T, Freman M, Lo W, et al. Modulation of plasmi-nogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Kidney Int 1997;51:164-172.
19. Vaughan DE. The renin-angiotensin system and fibrinoly-
sis. Am J Cardiol 1997;79:12-16.

Thank you for copying data from http://www.arastirmax.com